In 2009, the sales of the third terminal reached 1, 01.400 million yuan, up 26.7% year-on-year.
In August of 20 10, the year-on-year growth rates of total revenue and profit of pharmaceutical industry were 25.69% and 34.7 1% respectively. 2. The economic structure of medicine has improved.
In the fierce market competition, the pharmaceutical industry has changed the situation that the scale of pharmaceutical enterprises is too small and the layout is too scattered to some extent through various forms of alliance, merger and reorganization, and improved the concentration of production. Twenty-five enterprises in the pharmaceutical industry have entered the ranks of 520 large enterprises in China. The production concentration of the top 60 enterprises in the pharmaceutical industry is 35.7%, which is 16 percentage points higher than that at the end of the Eighth Five-Year Plan. A number of dominant brand-name enterprises have gradually developed and expanded in the fierce market competition. The number of producers of large-tonnage products such as penicillin, vitamin C, synthetic vitamin E, aspirin and paracetamol has been greatly reduced. The production concentrations of the top 50 preparations of tablets, powder injections, water injections, infusions and capsules reached 44.3%, 97.6%, 66.5%, 58.9% and 56.2% respectively.
The ownership structure has been further adjusted, basically forming a pattern in which public ownership is the mainstay and diversified ownership economies develop together. According to the output value, the proportion of the joint-stock economy in the whole industry increased from 12% in the early Ninth Five-Year Plan to 33.2%, the foreign-funded economy increased from 15% to 18.8%, and the state-owned economy decreased from 55% to 36. 1%.
The pace of reform of pharmaceutical circulation system has been accelerated, and pharmaceutical business has broken the pattern of state-owned commerce dominating the whole country under the long-term planned economy system, and the property right structure has developed in a diversified direction, and a number of standardized joint-stock enterprises and large enterprise groups have been established. The mode of operation began to change, and new modes of operation such as general agent, general distribution, centralized distribution and chain operation emerged constantly. In particular, chain operation has made great progress during the Ninth Five-Year Plan period. Nearly 200 pharmaceutical chain enterprises have been established in some large and medium-sized cities in China, and more than 5,000 pharmacies have been operated in chain stores. Many enterprises actively explore and pilot medical e-commerce.
The pharmaceutical economy in the western region has advanced by leaps and bounds. Sichuan has become the main producing area of traditional Chinese medicine in China. Yunnan, Guizhou, Qinghai, Gansu, Inner Mongolia, Guangxi and other provinces give full play to the advantages of local resources and become the production bases of ethnic medicine in China, which has promoted the local economic development and optimized the regional economic structure. 3. Promoting medicine through science and education has achieved certain results.
The pharmaceutical industry implements the policy of promoting medicine through science and education, and increases the research and development of new products. The output value rate of new products reached 15.8% in 199. During the Ninth Five-Year Plan period, pharmaceutical enterprises and scientific research units in China * * * obtained 5043 certificates of various new drugs, involving 2 1 12 varieties, including 108 national first-class new drug certificates.
The proportion of β -lactam series products with definite clinical efficacy and low toxic and side effects in antibiotic chemical raw materials increased from 15.3% at the end of the eighth five-year plan to 65438+20.3% at the end of 0999. Some key pharmaceutical intermediates, such as 6- aminopenicillanic acid (6-APA), 7- aminocephalosporanic acid (7-ACA), 7- amino 3- deacetoxycephalosporanic acid (7-ADCA), isophytol and trimethylhydroquinone, which are in short supply, have basically replaced imports. Natural vitamin E, roxithromycin, azithromycin and other important products have been industrialized, and new dosage forms such as controlled release, sustained release and transdermal delivery have been greatly developed.
A number of high-tech technologies, such as high-efficiency separation and purification technology, supercritical extraction technology, automatic control technology of production process, microcapsule technology and targeted technology, have been popularized and applied in pharmaceutical production. The output of penicillin was 0.7-0.8 tons/year at the end of the Eighth Five-Year Plan. The fermentation amount per cubic meter was increased to 1.0- 1. 1 ton, and the total yield of vitamin C was increased from 48% at the end of the Eighth Five-Year Plan to about 60%. The production of dexamethasone adopts a new process of biological dehydrogenation, which greatly reduces the cost and improves the international competitiveness. It not only replaces imports, but also exports in batches.
The development of new products of traditional Chinese medicine has been accelerated, especially in the treatment and prevention of cardiovascular and cerebrovascular diseases, digestive system, hepatitis and other diseases. Ling Xing Granules and Danshen Dripping Pills have passed the preliminary examination of the US FDA and entered clinical trials, which is another step for Chinese medicines to enter the international market. Tibetan medicine and other ethnic medicines have also moved from ethnic minority areas to the whole country.
The level of pharmaceutical equipment and production conditions have been greatly improved. During the Ninth Five-Year Plan period, a large number of advanced and applicable equipment, such as double-loop airlift fermentation reactors, dynamic extraction equipment and microporous membrane filters, were industrialized and widely used in the pharmaceutical industry. Some enterprises have passed ISO9000 certification. By the end of 2000, more than 780 pharmaceutical enterprises (workshops and dosage forms) had passed GMP certification, and the quality of drugs had been improved.
Some high-precision and sophisticated products in medical instruments, such as magnetic resonance, CT(X-ray computed tomography) and color B-ultrasound, have been industrialized, and the low-energy linear accelerator has basically been localized. Rotary gamma knife, digital subtraction imaging system, laser surgical instrument and optical fiber endoscope can all be mass-produced. China direct digital X-ray medical imaging system, which meets the international technical standards, has been successfully developed and put into clinical application in China, using high-power carbon dioxide cardiac laser. The product standards of medical devices are gradually in line with international standards, and the matching procurement of spare parts has begun to be internationalized. Nearly 65,438+000 enterprises have passed ISO9000 certification. 4. remarkable achievements have been made in opening up.
The pharmaceutical industry is one of the earliest industries opened to the outside world in China, and it is also a relatively successful industry in utilizing foreign capital. The top 20 pharmaceutical companies in the world have invested and set up factories in China. The pilot project of Sino-foreign joint venture pharmaceutical enterprises is progressing smoothly. The establishment of these foreign-funded enterprises not only introduced capital, but also brought new products, new technologies, new equipment and new management methods and concepts, which played a good demonstration role for domestic enterprises.